Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition

Shali Mazaki-Tovi1,2, Roberto Romero1,3,*, Juan Pedro Kusanovic1,2, Offer Erez1,2, Francesca Gotsch1, Pooja Mittal1,2, Nandor Gabor Than1, Chia-Lang Nhan-Chang1,2, Neil Hamill1,2, Edi Vaisbuch1,2, Tinnakorn Chaiworapongsar1,2, Samuel S. Edwin1, Jyh Kae Nien4, Ricardo Gomez4, Jimmy Espinoza1,2, Claire Kendal-Wright5, Sonia S. Hassan1,2 and Gillian Bryant-Greenwood6

1 Perinatology Research Branch, Intramural Division, NICHD/NIH/DHHS, Hutzel Women’s Hospital, Bethesda, MD, and Detroit, MI, USA
2 Department of Obstetrics and Gynecology, Wayne State University/Hutzel Women’s Hospital, Detroit, MI, USA
3 Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA
4 Center for Perinatal Diagnosis and Research (CEDIP), Hospital Sotero del Rio, P. Universidad Catolica de Chile, Puente Alto, Chile
5 University of Hawaii, John A. Burns School of Medicine, Department of Obstetrics, Gynecology and Women’s Health, Honolulu, HI, USA

Abstract

Objective: Visfatin, a novel adipokine originally discovered as a pre-B-cell colony enhancing factor, is expressed by amniotic epithelium, cytotrophoblast, and decidua and is over-expressed when fetal membranes are exposed to mechanical stress and/or pro-inflammatory stimuli. Visfatin expression by fetal membranes is dramatically up-regulated after normal spontaneous labor. The aims of this study were to determine if visfatin is detectable in amniotic fluid (AF) and whether its concentration changes with gestational age, spontaneous labor, preterm prelabor rupture of membranes (preterm PROM) and in the presence of microbial invasion of the amniotic cavity (MIAC).

Methods: In this cross-sectional study, visfatin concentration in AF was determined in patients in the following groups: 1) mid-trimester (n = 75); 2) term not in labor (n = 27); 3) term in spontaneous labor (n = 51); 4) patients with preterm labor with intact membranes (PTL) without MIAC who delivered at term (n = 35); 5) patients with PTL without MIAC who delivered preterm (n = 52); 6) patients with PTL with MIAC (n = 25); 7) women with preterm PROM without MIAC (n = 26); and 8) women with preterm PROM with MIAC (n = 26). Non-parametric statistics were used for analysis.

Results: 1) The median AF concentration of visfatin was significantly higher in patients at term than in mid-trimester; 2) Among women with PTL who delivered preterm, the median visfatin concentration was significantly higher in patients with MIAC than those without MIAC; 3) Similarly, patients with PTL and MIAC had a higher median AF visfatin concentration than those with PTL who delivered at term; 4) Among women with preterm PROM, the median AF visfatin concentration was significantly higher in patients with MIAC than those without MIAC.

Conclusions: 1) Visfatin is a physiologic constituent of AF; 2) The concentration of AF visfatin increases with advancing gestational age; 3) AF visfatin concentration is elevated in patients with MIAC, regardless of the membrane status, suggesting that visfatin participates in the host response against infection.

Keywords: Microbial invasion of the amniotic cavity (MIAC); pre-B cell colony-enhancing factor (PBEF); preterm labor; preterm prelabor rupture of membranes (preterm PROM); visfatin.

Introduction

Spontaneous preterm parturition is syndromic in nature [107, 112], and several mechanisms of disease have been implicated in the pathogenesis of this condition, including intrauterine infection/inflammation [11, 37, 40,
have shown that the inflammatory mediators, LPS, TNF-α, IL-6, and IL-1β up-regulate visfatin in the fetal membranes [92] and the up-regulation of its gene following IL-1β stimulation is modulated by the classic pro-inflammatory transcription factor NF-κB and AP-1 [57]. Although visfatin lacks a conventional secretion sequence its secretion from human amniotic epithelial cells [93], lymphocytes [123], neutrophils [55], and adipocytes [125, 128] has been demonstrated. Currently, its mechanism of secretion is unknown [128]; however, its exogenous application to explants of fetal membrane causes a number of pro-inflammatory modulators (i.e., TNF-α, IL-6, IL-1β, and IL-8) and enzymes (i.e., pro-MMP-1, -3, COX-2) to increase [94]. Furthermore, visfatin is anti-apoptotic for both amniotic epithelial and mesenchymal cells [58, 92] and neutrophils [55]. Collectively, these findings suggest that visfatin plays a role in the inflammatory process, in regulation of other pro-inflammatory cytokines, and in the preservation of immune cells.

The aims of this study were to determine if visfatin is detectable in amniotic fluid (AF) and whether its concentration changes with gestational age, spontaneous labor at term, in preterm labor rupture of membranes (preterm PROM), and in the presence of microbial invasion of the amniotic cavity (MIAC).

Materials and methods

Study design and population

A cross-sectional study was conducted by searching our clinical database and bank of biological samples. This study included women divided into eight groups: 1) mid-trimester (n = 75); 2) term not in labor (n = 27); 3) term in spontaneous labor (n = 51); 4) patients with preterm labor with intact membranes (PTL) without MIAC who delivered at term (n = 35); 5) patients with PTL without MIAC who delivered at term (n = 52); 6) patients with PTL with MIAC (n = 25); 7) women with preterm PROM without MIAC (n = 26); and 8) women with preterm PROM with MIAC (n = 26).

The indications for transabdominal amniocentesis in patients from groups 2–8 were the detection of MIAC and/or assessment of fetal lung maturity. A sample of amniotic fluid was transported to the laboratory in a sterile capped syringe for culture of aerobic/anaerobic bacteria and genital Mycoplasmas. Amniotic fluid white blood cell (WBC) count, glucose concentrations and Gram stain were also performed. The results of these tests were used for subsequent clinical management. Amniotic fluid not required for clinical purposes was centrifuged at 4°C for 10 min to remove cellular and particulate matter, and stored at −70°C. Patients in the mid-trimester did not have tests for the detection of inflammation/infection because the indication for amniocentesis was karyotype analysis.

Definitions

The inclusion criteria for normal pregnancy (groups 1, 2 and 3) were: (1) no medical, obstetrical or surgical complications; (2) absence of MIAC; (3) intact membranes at the time of amniocentesis; and (4) delivery of a term neonate (>37 weeks) with a birthweight above the 10th percentile [2, 43]. Preterm labor was defined as the presence of regular uterine contractions occurring at a frequency of at least two every 10 min, associated with...
cervical changes that required hospitalization before 37 weeks of gestation. MIAC was defined as a positive amniotic fluid culture for microorganisms. Preterm PROM was defined as amniorrhaxis prior to the onset of spontaneous labor before 37 weeks, diagnosed with the use of vaginal pooling, ferning, and/or a positive nitrazine test.

All women provided a written informed consent prior to the collection of amniotic fluid. The collection of samples for research was approved by the Institutional Review Boards of Wayne State University, Pennsylvania Hospital, and Sotero del Rio Hospital, as well as the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services. These samples have been used in previous studies of cytokines in the amniotic fluid.

**Human visfatin C-terminal immunoassay**

Concentrations of visfatin in amniotic fluid were determined using a specific and sensitive enzyme immunoassay (Phoenix Pharmaceuticals Inc., Belmont, CA). Visfatin C-terminal assays were validated in our laboratory for use with human amniotic fluid prior to the conduction of this study. Validation included spike and recovery experiments, which produced parallel curves indicating that amniotic fluid matrix constituents did not interfere with the antigen-antibody binding in this assay system. Visfatin enzyme immunoassays are based on the principle of competitive binding and were conducted according to recommendations of the manufacturer. Briefly, assay plates were pre-coated with a secondary antibody and the non-specific binding sites were blocked. Standards and samples were incubated in the assay plates along with primary antiserum and biotinylated peptide. The secondary antibody in the assay plates bound to the Fc fragment of the primary antibody whose Fab fragment competitively bound with both the biotinylated peptide and peptide standard or targeted peptide in the samples. Following incubation, the assay plates were repeatedly washed to remove unbound materials and incubated with a streptavidin-horseradish peroxidase (SA-HRP) solution. Then, unbound enzyme conjugate was removed by repeated washing and a substrate solution was added to the wells of the assay plates. Color developed in proportion to the amount of biotinylated peptide-SA-HRP complex but inversely proportional to the amount of peptide in the standard solutions or the samples. Color development was stopped with the addition of an acid solution and the intensity of color was read using a programmable spectrophotometer (SpectraMax M2, Molecular Devices, Sunnyvale, CA). Amniotic fluid concentrations of visfatin C were determined by interpolation from individual standard curves composed of human visfatin peptide. The calculated inter- and intra-assay coefficients of variation for Visfatin C-terminal immunoassays in our laboratory were 5.2% and 2.3%, respectively. The lower limit of detection (sensitivity) was calculated to be 0.04 ng/mL.

**Statistical analysis**

Shapiro-Wilk and Kolmogorov-Smirnov tests were used to test for normal distribution of the data. Data are presented as mean ± SD for normally distributed parameters and as median (range) for those which were not normally distributed. Non-parametric methods were used to perform the statistical analysis for parameters which were not normally distributed, such as amniotic fluid visfatin concentration. Comparisons between groups for continuous variables were performed using the Kruskal-Wallis test with post hoc analysis (Mann-Whitney U-test). The Chi-square or Fisher’s exact tests were used for categorical variables. Comparisons among groups for normally distributed parameters were performed using one-way ANOVA with Bonferroni adjustment for the calculated P-value in order to maintain the significance level at 0.05. Correlation between amniotic fluid concentrations of visfatin and gestational age, amniotic fluid WBC count and amniotic glucose concentration was conducted with Spearman’s rank correlation. A P-value of 0.05 was considered statistically significant. The statistical package used was SPSS v.14.0 (SPSS Inc., Chicago, IL, USA).

**Results**

Tables 1 and 2 display the clinical and obstetrical characteristics of the study groups. There was no significant difference in the gestational age at sampling between women at term in labor and those at term not in labor.

**Table 1** Clinical and demographic characteristics of patients with spontaneous preterm labor and intact membranes.

<table>
<thead>
<tr>
<th></th>
<th>Preterm labor who delivered at term without MIAC (n = 35)</th>
<th>Preterm labor with MIAC (n = 25)</th>
<th>Preterm labor who delivered preterm without MIAC (n = 52)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (years)</td>
<td>23.0 (16–38)</td>
<td>23.0 (16–32)</td>
<td>24.5 (15–44)</td>
<td>NS</td>
</tr>
<tr>
<td>Gravidity</td>
<td>3.0 (1–11)</td>
<td>3.0 (1–9)</td>
<td>3.0 (1–11)</td>
<td>NS</td>
</tr>
<tr>
<td>Parity</td>
<td>1.0 (0–7)</td>
<td>1.0 (0–6)</td>
<td>1.0 (0–5)</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age at amniocentesis (weeks)</td>
<td>28.5±3.2</td>
<td>26.2±4.6</td>
<td>27.2±4.2</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age at delivery (weeks)</td>
<td>38.5±1.4</td>
<td>26.9±5.0</td>
<td>30.3±4.9</td>
<td>P &lt; 0.01*</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>2910±471</td>
<td>1103±687</td>
<td>1514±826</td>
<td>P &lt; 0.05*</td>
</tr>
</tbody>
</table>

Values are expressed as median (minimum–maximum) or as mean ± SD.

MIAC – microbial invasion of the amniotic cavity; NS – not significant.

*ANOVA with Bonferroni adjustment P < 0.01 between preterm labor with MIAC and preterm labor without MIAC, preterm labor with MIAC and preterm labor who delivered at term, and between preterm labor without MIAC and preterm labor who delivered at term.

*ANOVA with Bonferroni adjustment P < 0.01 between preterm labor with MIAC and preterm labor without MIAC, preterm labor with MIAC and preterm labor who delivered at term, and P = 0.03 between preterm labor without MIAC and preterm labor who delivered at term.
Table 2  Clinical and demographic characteristics of patients with preterm prelabor rupture of membranes (preterm PROM).

<table>
<thead>
<tr>
<th></th>
<th>Preterm PROM without MIAC</th>
<th>Preterm PROM with MIAC</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 26)</td>
<td>(n = 26)</td>
<td></td>
</tr>
<tr>
<td>Maternal age (years)</td>
<td>23.0 (15–37)</td>
<td>29.0 (17–39)</td>
<td>NS</td>
</tr>
<tr>
<td>Gravidity</td>
<td>3.0 (1–9)</td>
<td>5.0 (1–12)</td>
<td>NS</td>
</tr>
<tr>
<td>Parity</td>
<td>1.0 (0–6)</td>
<td>2.0 (0–7)</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age at amniocentesis (weeks)</td>
<td>29.7 ± 3.7</td>
<td>28.4 ± 3.8</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age at delivery (weeks)</td>
<td>33.0 ± 3.1</td>
<td>29.8 ± 4.7</td>
<td>P = 0.01</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>2023 ± 648</td>
<td>1418 ± 605</td>
<td>P &lt; 0.01</td>
</tr>
</tbody>
</table>

Values are expressed as median (minimum–maximum) or as mean ± SD.
MIAC – microbial invasion of the amniotic cavity; NS – not significant.

Figure 1  Amniotic fluid visfatin concentrations in women with a normal pregnancy in the mid-trimester and in those at term not in labor. The median amniotic fluid concentration of visfatin was significantly higher in women at term than those in the mid-trimester.

Figure 2  Amniotic fluid concentration of visfatin in women with spontaneous preterm labor and intact membranes. The median amniotic fluid visfatin concentration was significantly higher in patients with microbial invasion of the amniotic cavity (MIAC) than in those who delivered at term without MIAC. Similarly, the median amniotic fluid visfatin concentration was significantly higher in patients with MIAC compared to those without MIAC who delivered preterm. Among women with preterm labor without MIAC, there was no difference in the median amniotic fluid concentration of visfatin between women with spontaneous preterm labor who delivered at term or preterm.
Amniotic fluid visfatin concentration was significantly higher in patients with MIAC than those without MIAC.

Amniotic fluid visfatin concentrations in preterm PROM

Among women with preterm PROM, the median amniotic fluid visfatin concentration was significantly higher in patients with MIAC than in those without MIAC (60.5 ng/mL, 10.2–289.9 vs. 31.7 ng/mL, 4.9–124.3, respectively; P = 0.01) (Figure 3). Among patients with preterm PROM with intact membranes who delivered preterm and those with preterm PROM, there was no significant difference in the median amniotic fluid visfatin concentration between women with and without MIAC.

Amniotic fluid visfatin concentrations were negatively correlated with both amniotic fluid glucose concentration (r = −0.21, P = 0.002) and the amniocentesis-to-delivery interval (r = −0.29, P = 0.001). Amniotic fluid visfatin concentrations were positively correlated with the amniotic fluid WBC count (r = 0.48, P = 0.001) and gestational age at amniocentesis in women with normal pregnancy (r = 0.69, P < 0.001).

Discussion

Principal findings of the study

1) Immunoreactive visfatin is a physiologic constituent of the amniotic fluid; 2) the median amniotic fluid concentration of visfatin increase with advancing gestational age; 3) among women with spontaneous PTL and intact membranes, those with MIAC had a significantly higher median amniotic fluid visfatin concentration compared to those without MIAC who delivered either at term or preterm; 4) similarly, in patients with preterm PROM, the median amniotic fluid visfatin concentration was significantly higher in women with MIAC as compared to those without MIAC; 5) amniotic fluid visfatin concentrations were negatively correlated with amniotic fluid glucose concentrations and with amniocentesis-to-delivery interval; and 6) amniotic fluid visfatin concentrations were positively correlated with the amniotic fluid WBC count.

Visfatin, a novel adipokine and an ancient inflammatory mediator

Visfatin is a novel adipokine [8, 22, 33, 48, 126] that has been previously identified as a growth factor for early B cells, termed pre-B cell colony-enhancing factor (PBEF) [55, 74, 92, 123, 136]. Its gene, mapped on the long arm of chromosome 7 (7q22) [91], has only one large open reading frame which encodes a polypeptide of 473 amino acids with an estimated molecular weight of 52 kDa [123]. The expression of visfatin/PBEF has been reported in mammals [20, 74, 77, 89, 91–94, 123, 129, 130, 136] as well as in fish [34], invertebrates [85] and bacteria [73]. Its high conservation suggests that visfatin/PBEF probably plays an important biological role. In humans, visfatin is produced by visceral adipose tissue [54, 126]. Nevertheless, it is also expressed in large amounts in bone marrow, liver, muscle [123, 126], heart, lung, kidney, placenta [123], monocytes and neutrophils [55].

What is the physiological role of visfatin?

While the specific physiological role of visfatin has not been completely elucidated, there is evidence to suggest that visfatin has at least three major features: immunoregulatory, metabolic, and intracellular phosphoribosyl tranferase activity.

Evidence in support that visfatin has immunoregulatory properties include: 1) It synergizes with IL-7 and stem cell factor to promote the growth of B cell precursors [123]; 2) visfatin up-regulates the production of pro- and anti-inflammatory cytokines (e.g., IL-1β, IL-6, IL-10, and
TNF-α) in human monocytes [84, 92]; 3) visfatin mRNA expression is up-regulated in neutrophils harvested from septic, critically ill patients [55]. It is also expressed [55, 87, 127, 135], synthesized, and released [55] by neutrophils in response to inflammatory stimuli and contributes to prolonged neutrophil survival in clinical sepsis [55]; 4) nuclear factor-κB (NF-κB) and AP-1, members of the transcription factor family, have been implicated in the up-regulation of pro-inflammatory cytokines and the amplification and perpetuation of the inflammatory response [59, 64, 82]. Both have been reported to mediate the up-regulation of PBEF gene in human amniotic epithelial cells culture after an inflammatory stimulus [57], and visfatin induces NF-κB transcriptional activity in human endothelial cells [1]. Furthermore, the genomic organization of the gene coding for visfatin revealed a NF-κB binding element in the third intron [91]; 5) gene expression of this adipokine is increased in lung tissue of animals with acute lung injury [35, 36, 136]; 6) polymorphisms in the gene for visfatin are associated with both increased and decreased risk for acute respiratory distress syndrome [7, 69]; and 7) patients with inflammatory bowel disease, a chronic inflammatory condition, have an elevated serum visfatin concentration as well as an increased expression of visfatin mRNA in intestinal epithelium [84]. Similarly, plasma [96] and synovial fluid [90] concentrations of visfatin are higher in patients with rheumatoid arthritis than in healthy controls.

The evidence for the metabolic effects of visfatin include: 1) visfatin-deficient mice have an impaired glucose tolerance and a decrease in insulin secretion after glucose injection than in control animals [101]; 2) in vitro exposure to glucose results in an increase in its secretion by adipocytes [47]; 3) visfatin exhibits insulin mimetic properties [54, 134]; 4) administration of glucose to human subjects is associated with elevation in circulating visfatin [47]; 5) a visfatin promoter polymorphism is associated with increased risk for Type-2 diabetes mellitus [69, 137]; 6) patients with Type-2 diabetes mellitus have a higher plasma visfatin concentration than non-diabetic subjects [21, 24, 27, 46, 67, 124]; 7) visfatin serum concentrations are higher in patients with gestational diabetes mellitus (GDM) than in normal pregnant women [63, 66]. Of note, plasma visfatin concentrations in the first trimester predict insulin sensitivity during the second trimester [75], and a positive correlation between fasting glucose and visfatin concentrations was reported in normal pregnant women and in those with GDM [45]; and 8) circulating concentration of visfatin correlates with quantity of intra-visceral fat as estimated by computed tomography [124] as well as with BMI [8, 18, 124] and waist circumference [30].

Visfatin is also an intracellular phosphoribosyl transferase that is involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD) via the salvage pathway. NAD is an important coenzyme for the regulation of numerous metabolic pathways and for several NAD dependent deacetylases. This enzymatic action of visfatin has been confirmed from its bacterial [73] and murine homologues [119].

**Visfatin is a physiological component of the amniotic fluid**

This is the first study reporting the presence of visfatin in amniotic fluid. Visfatin was detectable in the amniotic fluid of all patients included in this study, from the early second trimester until 42 weeks of gestation, suggesting that visfatin is a physiologic component of human amniotic fluid. Moreover, visfatin concentrations increased with advancing gestational age, as indicated by its positive correlation with gestational age at amniocentesis.

The source of this protein in the amniotic fluid is currently unknown. Several studies have reported the detection of visfatin in the maternal circulation [17, 26, 63, 66, 71]. In accordance with the increased amniotic fluid visfatin concentrations during pregnancy reported herein, maternal serum visfatin concentration also increases with advancing gestation [75]. In addition, visfatin is expressed in the myometrium [25] and decidua [92]. Circulating visfatin is also detectable in cord blood [10, 71, 72], where its concentration correlates with birth weight percentile [10, 72].

The placenta was one of the first organs reported as a tissue in which visfatin is expressed [123]. Subsequently, several studies have demonstrated gene expression of visfatin in amniotic cell culture [57, 58, 74, 89, 91]. Visfatin was immunolocalized in the amniotic epithelium, mesenchymal cells of the amniotic connective tissue, chorionic cytotrophoblast and parietal decidua [74, 89, 91–94]. Importantly, in vitro studies have demonstrated that amniotic cells secrete visfatin [58, 93]. In the study reported herein, visfatin was detectable in the amniotic fluid in normal pregnancy as early as the beginning of the second trimester. This finding is consistent with the earliest expression of visfatin in fetal membranes reported at 13 weeks of gestation [92].

**Amniotic fluid visfatin concentration increases with advancing gestation**

The findings that the median amniotic fluid concentration of visfatin was significantly higher at term than in midgestation, and was positively correlated with gestational age at amniocentesis are novel. Fetal membranes secrete this cytokine [58, 92, 93] and acute or chronic mechanical stretching of the fetal membranes is associated with increased expression and secretion of visfatin [58, 88, 89]. The chorioamniotic membranes are distended by 40% at 25–29 weeks of gestation, 60% at 30–34 weeks of gestation, and 70% or more at term [12, 79, 98]. The increase in the median concentration of amniotic fluid visfatin with advancing gestation and the
positive correlation with gestational age support the aforementioned reports regarding the association between fetal membranes stretching and increased expression and secretion of visfatin. In addition, visfatin has anti-apoptotic properties, and can exert its effect on amniotic epithelial cells [58], fibroblasts [93] and neutrophils [55]. It is tempting to postulate that the physiological increase of visfatin in amniotic fluid with advancing pregnancy aims to protect the fetal membranes from apoptosis and thus, prevent preterm PROM. Alternatively, given the unique combination of immunoregulatory and anti-apoptotic properties of visfatin, it can be argued that its concentration increases in the presence of MIAC as a defense mechanism against the inflammatory process or to help sustain neutrophils in the amniotic fluid.

Amniotic fluid visfatin concentration increases in the presence of infection

Patients with MIAC had a higher median amniotic fluid concentration of visfatin compared to those with a negative amniotic fluid culture, regardless of the membrane status. Indeed, this is the first in vivo study demonstrating an association between visfatin and infection in humans. Moreover, visfatin concentration correlated with well-established indices of intra-amniotic inflammation such as amniotic fluid glucose concentrations (r = -0.21, P = 0.002) and WBC count (r = 0.48, P = 0.001). These parameters are being routinely used to diagnose intra-amniotic inflammation [117, 118]. Finally, amniotic fluid visfatin concentrations were negatively correlated with the amniocentesis-to-delivery interval (r = -0.29, P = 0.001). Collectively, these new findings may point to a regulatory role of visfatin in the inflammatory response to acute infection.

The cross-sectional nature of this study does not allow us to discern a cause and effect relationship between amniotic fluid visfatin and infection; however, our hypothesis regarding the role of visfatin in intra-amniotic infection is supported by the following findings: 1) visfatin can exert an anti-apoptotic effect on neutrophils, amniotic epithelial cells and fibroblasts [55, 58, 93]; thus, it may protect fetal membranes as well as neutrophils in amniotic fluid against apoptosis induced by infection or labor. Indeed, it is possible that the higher median visfatin concentration in patients with MIAC than those without intra-amniotic infection is the result of secretion from neutrophils into the amniotic fluid; 2) exposure of cultured amniotic cells to lipopolysaccharide stimulates the secretion of visfatin, and treatment with an antisense oligonucleotide to visfatin obliterate its secretion [93]; 3) several inflammatory mediators, such as IL-6, IL-1β and TNF-α have been shown to significantly increase the expression of visfatin in amniotic epithelial cells [91]. Furthermore, in vitro, visfatin induces a dose-dependent increase in the expression of IL-6 in amniotic epithelial cells and fetal membranes [92]; Noteworthy, IL-6, TNF-α, IL-1 and IL-8 have been implicated in intra-amniotic infection [3, 14, 23, 28, 29, 32, 42, 51, 102, 103, 111, 113–116, 133]; 4) visfatin induces, in a dose-dependent manner, the expression and secretion of IL-8, a potent chemotactic agent; 5) results of microarray studies reveal that the visfatin gene is up-regulated during labor (an inflammatory state) in myometrium [25] and fetal membranes [94]. Consistent with the findings of the present study, visfatin gene expression is higher in fetal membranes taken from patients with preterm labor and infection compared to those without infection [74, 91].

In conclusion, this is the first in vivo study describing the presence of visfatin in amniotic fluid and its association with acute infection in humans. While the physiological roles of visfatin are undoubtedly complex and need further study, the findings of the present report suggest that visfatin has a role in normal gestation, as well as in the inflammatory response associated with infection. Thus, increased secretion of this protein from fetal membranes, and possibly from intra-amniotic leukocytes in the presence of infection, may be an attempt to protect the epithelial cells from apoptosis. The anti-apoptotic effect of visfatin on epithelial cells may have clinical implications. Intra-amniotic administration of visfatin, or therapeutic manipulation of its concentrations, may help to prevent preterm PROM. The potential of therapeutic intervention may be of special benefit to patients with high risk for preterm PROM, such as those with multiple gestations and over distended uterus.

Acknowledgment

This research was supported in part by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS.

References


[18] Chen TF, Chenb Sc YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril. 2007;...


Hufton SE, Moerkerk PT, Brandwijk R, De Bruine AP, Hirsch E, Wang H. The molecular pathophysiology of...


